Article Text

FRI0237 Study of the antibody titer by influenza vaccination in rheumatoid arthritis patients treated with biological agents
  1. H. Ishikawa1,
  2. H. Kanda1,
  3. D. Kida1,
  4. A. Kaneko1,
  5. M. Katayama2,
  6. T. Sato1
  1. 1Department of Orthopaedic Surgery and Rheumatology
  2. 2Rheumatology, Nagoya Medical Center, Nagoya, Japan


Background Biologic agents might suppress the immune response to influenza vaccines, but, the report is limited to the number of papers.

Objectives The aim is the study to compare antibody titers change after influenza vaccination for rheumatoid arthritis (RA) patients who have been treat with methotrexate (MTX ;contorol), abatacept (ABT), tocilizumab (TCZ), golimumab (GLM).

Methods 189 patients with RA (MTX;n=56, ABT;n=37, TCZ;n=79, and GLM;n=17) received inactive trivalent influenza vaccination (A/H1N1, A/H3N2, B/B-1 strains). Antibody titer were measured before and one month after vaccination using the haemagglutination inhibitory assay.

Results Compared with the control, Biologic agents, but only showed a difference of type B in seroprotection rate, there was no difference in the seroconversion rate (table 1). In seroconversion rates tended to be lower in all strains ABT. It was a significant difference in all strains to TCZ. No difference was observed in the control and GLM. In seroprotection rate, ABT was still lower value. It was a significant difference in the same manner in all strains to TCZ, Only A/H3N2, the control difference was observed, there was no difference in the GLM (table 2).

Conclusions In our result, There was little difference between the control and Biologics (ABT, TCZ, GLM). The patients treated with ABT, antibody titers were low, and was a significant difference of both seroprotection rate and seroconversion rate to TCZ. The patients thought that the examination of the multiple dose etc. of the vaccine was necessary in the future.

Acknowledgements Disclosure of Interest: None Declared

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.